When it comes to managing equine degenerative joint disease (DJD), a comprehensive approach is essential for long-term success. A multimodal treatment plan requires careful consideration and communication.
Here are a few things Sherry Johnson, DVM, MS, PhD, DACVSMR, senior partner at Equine Sports Medicine in Pilot Point, Texas/Scottsdale, Arizona, keeps in mind when designing a patient’s DJD treatment plan:
- Each horse requires a varied level of intervention.
- Never underestimate the importance of exercise.
- Balance medical management with physical rehabilitation.
“I often incorporate Adequan i.m.® when I need to maintain systemic levels of PSGAG over time, and I prescribe it alongside other treatments, whether they be medical or physical,” said Johnson. “By combining appropriate medical interventions with targeted physical therapy and customizing the approach to the horse’s unique needs, we create a comprehensive strategy that treats the disease at the cellular level, while also rehabilitating the whole body.”
Adequan® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
INDICATIONS
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequan.com.
Related Reading
Stay in the know! Sign up for EquiManagement’s FREE weekly newsletters to get the latest equine research, disease alerts, and vet practice updates delivered straight to your inbox.
